10:30AM-12PM, January 26, 2015 – NGS Applications: Impact of Genomics on Cancer Care – LIVE @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA
Reporter: Aviva Lev-Ari, PhD, RN
Real Time Conference Coverage with Social Media
@Computer History Museum by Dr. Aviva Lev-Ari, PhD, RN
Session Chair: Frank S. Ong, Illumina (Chair)
LIVE FROM THE PODIUM
Changing aspects of Genomics
10:30AM – 10:45AM John Leite, Illumina
The Path to Adoption of NGS for Clinical Oncology Management
- Research – Computing Discovery
- Translation
- Clinical
Knowledge GAP CRISIS – Omics vs Paths
- testing
- reimbursement – How will NGS help profitability by lowering the Cost of Testing
- Enabling Oncology applications – COmplete clinical SOlutions
- TRADITIONAL APPROACH: One drug—>> COmpanion Test (single target) –>>> Patients
- PRECISION ONCOLOGY — PHARMA ALLIANACE WITH AZ, JENSEN, — UNIVERSAL SOLUTION REQUIRES COLLABORATIONS WITH CANCER TREATMENT CENTERS
- Clinical NGS Standard – Suite of standards: SAmple processing, content, sequencing
- Performance evaluation: Change in management behavior, how tests are ordered, cost to be low
10:45AM – 11:00AM Mike Nolan, Thermo Fisher
Collaboration in an Ecosystem
Pioneering the Path to Precision Oncology Through Next-Generation Sequencing
- Ion Torrent NGS Cancer Research Tools
- 75% of Cancer patients are treated in the community
- >600 types of tests for clinical Research labs
- Global OncoNetwork COnsorsium
- Development of Regulated NGS Oncology SolutionsL From Academic Center to the Clinic
- Oncomine: Cancer Research Panel
- NCI Match Trial –
- New LiquidBiopsy – NGS Workflow — ONE blood cell
- Leading the way in NGS Oncology Genomics
11:00AM – 11:15AM Brad Gray, NanoString Technologies
Improving Cancer Care Through Localized Tumor Profiling
LIVE from the PODIUM
- Improving Cancer Care Through localized Tumor Profiling
- Cancer Translational Paradox: tumor goes smaller with Therapy
- Automated workflow – NanoString Advantage: Localized profiling –>>Locatiles
- Molecular RNA – NOT Sequencing: nCOUNTER: Powerful CHemistry, simple Workflow
- nanoString: 2008 gene expression, gene fusion, multiple proteins
- 600 Peer review papers published using this technology
- 50% – install based in CHina
- major Pharma
- Clinical Diagnostics: Pfizer
- DIagnostics Lab: Washington Univeristy, St. Louis – Breast Cancer Assay
- Companion Diagnostics: BioPharma: Celgene – Lymphoma, Leukhemia
- Prosigna: Informing Breast Cancer Treatment Decisions – 30 Worlworld
- Companion DIagnostics: Celgene Collaboration Clinical Labs offer Prosigna Testing – Celgene is funding the development
- 250 days from when a paper was published to having a test to deliver
- Multiplex gene expression and high growth Companion Diagnostics
11:15AM – 11:30AM Mark Erlander, Trovagene CLIA, NASDAQ
Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples
LIVE FROM THE PODIUM
- Circulating Tumor DNA (ctDNA): Main advantages
- Detection of mutation genetics
- Metastatic Cancer: Monitoring Mutation Level
- Platforme: DCP – Precision Cancer Monitoring
- Samples in Urine and Plasma: Proprietary Mutant Allele Enrichment Method
- how to measure changes: in plasma circulating DNA in less quantity – In urine better for harvesting DNA
- Prospective blinded study of BRAF V600E Mutation
- Detection in Cell-Free DNA of Patients with Systemic Historic ctDNA Improve Genotyping Over Tissue Biopsies in Histiocyctic
- Correction between Longitudinal ctDNA and Radiographic Response
- colonorectal: Urine pationet and Plasma circualting Metastesis cells from the LIVER
- high concordance between Urine and Palsma ctDNA : Monitoring During and Post Surgery of KRAS
- Pancreatic Cancer, collaboration with Copenhagen University: IF KRAS IS HIGH SURVIVAL WILL BE LOW — surgery intervention is critical for survival
- NSCLC – Lung Cancer: EGFR – Cost of Biopsy for Lung Cancer $1400, healthcare cost burden – test of urine – lower the burden of Cost
11:30AM – 11:45AM Tom Willis, Sequenta
Immune Response Profiling: Actionable Insights Through Next-Gen Sequencing
LIVE from the PODIUM
- The Immune System is involved in almost every aspect of Human Health
- Immune System Diversity is created through DNA Recombination: T and B cells
- NGSis used for DNA Recombination of T and B Cells
- Application system of bar codes for every cell sequence – cataloguing
- Clinical validation – ClonoSIGHT for Lymphoid Cancers – CLL
- 1 Million patients a year — WHO will benefit?? – Clinical Needs for Testing
- Using ClonoSIGHT to measure MRD – Monitoring after Transplant
- bar code of cancer cells using ClonoSIGHT to revolutionize MRD Testing
- Opportunity to Guide Therapy in Hematology: Multiple Myeloma
11:45 Audience Q&A
#startup #biotech #pharmanews @BiotechNews
#science #innovation @BloombergTV
Leave a Reply